GTBP GTBP
Company Profile ↓Company Overview
GTBP (GTBP) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -82.16% |
| 6 Months: | -39.18% |
| 3 Months: | -16.45% |
| 1 Month: | -30.98% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 82.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 19.00K | 44.00K | 60.00K | 0 | 8.00K | -2.00K | 7.00K | 20.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -347.00K | -74.00K | -140.00K | -101.00K | -104.00K | -549.00K | -1.81M | -1.43M | -2.78M | -3.90M | -2.12M | -2.53M | -1.54M | -1.28M | -126.86M | -7.16M | -5.16M | -234.66M | -4.06M | -2.28M | -8.86M | 1.07M | -1.56M | -1.95M | -29.00M | -4.38M | -5.95M | -5.44M | -3.01M | -7.02M | -3.67M | -3.62M | -3.12M | -3.09M | -3.91M | -3.60M | -1.93M | -1.51M | -3.38M | -2.85M |
| Net Income | 468.00K | -306.00K | -319.00K | -371.00K | -262.00K | -4.22M | -20.52M | 26.86M | -1.69M | 25.95M | 1.54M | -3.63M | -5.06M | -2.46M | -130.62M | -10.09M | -9.08M | -235.78M | -4.51M | -2.79M | -29.88M | -1.71M | -17.42M | -2.88M | -29.68M | -4.86M | -5.45M | -5.44M | -2.98M | -6.88M | -227.00K | -1.99M | -2.42M | -2.27M | -3.71M | -3.41M | -776.00K | -30.17M | 8.30M | -2.83M |
| Diluted EPS | 0.00 | 0.00 | - | 0.00 | 0.00 | -0.01 | -8.61 | 4,907,238.00 | 0.71 | 1.49 | 18.22 | -39.65 | -26.36 | 479,053.00 | -8.15 | -0.20 | 50,117,977.00 | -4.70 | -0.09 | - | - | -0.02 | - | - | - | - | - | - | -0.10 | -0.22 | -0.21 | -1.49 | -1.77 | -1.64 | -2.17 | -1.53 | -0.33 | -10.92 | 1.04 | -0.11 |
| R&D Expense | 0 | 0 | 0 | 0 | 0 | 0 | 250.00K | 0 | 225.00K | 225.00K | 250.00K | 250.00K | 144.00K | 241.00K | 526.00K | 3.47M | 3.25M | 1.11M | 834.00K | 154.00K | 671.00K | 324.00K | 12.00K | 84.00K | 1.64M | 639.00K | 1.01M | 2.09M | 1.14M | 2.74M | 1.65M | 2.10M | 1.36M | 777.00K | 1.78M | 1.31M | 1.10M | 363.00K | 634.00K | 413.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.00K | 26.00K | 342.00K | 368.00K | 61.00K | 27.00K | 0 | 0 | - | 0 | 0 | - | - | - | - | - |
| Gross Profit | -54.00K | -22.00K | 248.00K | 142.00K | 4.00K | 27.00K | 0 | 0 | - | - | - | - | - | - | - | - |
| Operating Income | -2.50M | -3.93M | -3.51M | -793.00K | -2.40M | -8.93M | -9.37M | -135.57M | -250.07M | 16.06M | -6.76M | -57.52M | -21.26M | -13.58M | -14.36M | -12.42M |
| Net Income | -3.00M | -3.70M | -5.17M | -501.00K | -23.49M | -32.73M | 9.77M | -144.17M | -259.19M | -38.65M | -28.30M | -58.01M | -20.88M | -7.60M | -13.16M | -28.35M |
| Diluted EPS | - | - | - | - | - | - | 119.91 | -8.60 | -5.16 | - | - | - | -19.66 | -5.64 | -6.94 | -6.68 |
| R&D Expense | 179.00K | 17.00K | 0 | 0 | 0 | 1.00M | 975.00K | 1.07M | 9.07M | 1.67M | 485.00K | 9.59M | 8.81M | 6.47M | 5.80M | 3.47M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Sep 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Sep 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 185.00K | 129.00K | - | 226.00K | 147.00K | 888.00K | 54.00K | 25.00K | 254.37M | 25.40M | 396.00K | - | - | 5.66M | 32.17M | 16.74M | 14.11M | 4.23M | 7.12M | 4.32M | 8.11M |
| Total Equity | - | -5.47M | -5.10M | - | -6.34M | -6.33M | -29.57M | -61.83M | -18.92M | 251.69M | 11.37M | -19.31M | -27.50M | -29.78M | -29.43M | 21.91M | 11.73M | 7.48M | -1.67M | -25.88M | 3.00M | 5.79M |
| Cash & Equivalents | 1.29M | 54.00K | 92.00K | 61.00K | 123.00K | 43.00K | 855.00K | 47.00K | 19.00K | 576.00K | 60.00K | 28.00K | - | - | 5.30M | 8.97M | 5.67M | 1.08M | 3.95M | - | - | 6.81M |
| Total Liabilities | - | 5.65M | 5.23M | - | 6.56M | 6.48M | 30.46M | 61.89M | 18.95M | 2.68M | 14.03M | 19.71M | - | - | - | 10.26M | 5.00M | 6.63M | - | 31.04M | 1.32M | - |
| Current Liabilities | - | 5.65M | 5.23M | - | 6.56M | 6.38M | 29.83M | 61.17M | 18.95M | 2.68M | 14.03M | 19.71M | - | - | 35.09M | 10.26M | 4.94M | 6.63M | 5.90M | - | - | 2.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.53M | -963.00K | -987.00K | -442.00K | -1.75M | -4.66M | -1.93M | -5.43M | -10.68M | -3.66M | -7.26M | -15.61M | -15.22M | -8.85M | -12.90M | -12.91M |
| Investing Cash Flow | - | 0 | -2.00K | 0 | -6.00K | -1.00K | 0 | -4.00K | -36.00K | 200.00K | 0 | -23.04M | 12.14M | -2.01M | 12.89M | - |
| Financing Cash Flow | 296.00K | 1.00M | 930.00K | 425.00K | 2.58M | 3.85M | 1.90M | 5.99M | 10.20M | 3.43M | 12.53M | 42.32M | -224.00K | 6.27M | 2.98M | 15.78M |
| Capital Expenditure | - | -0 | -2.00K | -0 | -6.00K | -1.00K | -0 | -4.00K | -36.00K | -0 | - | - | - | - | - | - |
| Free Cash Flow | - | -963.00K | -989.00K | -442.00K | -1.75M | -4.66M | -1.93M | -5.43M | -10.71M | -3.66M | - | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 229.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -490.9% | -84.6% | 72.5% | 38.6% | 6.6% | 100.0% | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -22,700.0% | -15,107.7% | -1,027.5% | -215.5% | -3,927.9% | -33,063.0% | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | -27,227.3% | -14,230.8% | -1,512.0% | -136.1% | -38,506.6% | -121,207.4% | - | - | - | - | - | - | - | - | - | - |
| ROE % | 54.8% | 72.5% | 81.6% | 7.9% | 79.4% | 52.9% | -51.6% | -57.3% | -2,279.6% | 200.1% | 96.1% | -264.8% | -178.0% | -101.6% | 788.1% | -490.0% |
| ROCE % | 45.7% | 77.0% | 55.5% | 12.7% | 8.3% | 14.6% | 49.5% | -53.9% | -2,199.4% | -83.1% | 23.0% | -262.5% | -180.2% | -181.6% | 860.1% | -214.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GTBP
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE5UdV9HZnFWb1JVd0VqT1ZidXhpelZSVjNLY3ptNm0xVGF4Y0FEQ0NjVUN1eE1CMXlSY1B1T1NXQ3l5aExxNE5GNHJSRGpvd2ZRaVhEamQyek9ITVMwZnozR1VOS2U?oc=5" target="_blank">GT BIOPHARMA INC (GTBP) Stock Ch…
GTBP Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBmaldMaWJOa0VYdnFrMGc4OU90R1g1V0xNTkNUTGFvVmdvLW9FOVRPcENqM0hyeVJFRmxpRy1TRUtUcllZTV9nQlkyTEN4LUV5djN4QWV0UzlqZ3F6clJEdV9pVDlyVTFmLU9Uam10bzlSM1ZPNno5UFlB?oc=5" target="_blank">GTB…
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPYV9BQy1DMUNQWVRfWE1yTG9fY0p2UVpBc3pFWk1tRUxrUlNuaDhSVVZCTXBRN0VRYVh5ZGozRGlLT1RJa0p2dlJub0ZJWi1YSTd2NzVFdzdYV2NzV0JwQ3B2c2pBYTNyOHNnX1BZVFl0cE9WdnoxSENPSGswRUFKMjVB?oc=5" target=…
New prostate cancer trial tests NK cell drug for hard-to-treat tumors - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQY0NjMm80QXREZzhzQ09vSXZIMmh6ZHNZbks1VkpSNjVJVDVDZGJMbkNxS3h6MXQ2cW1PYm1vMWxPOF9ydzM0OVA4by1ORUd5Wnd3VGlZTmNKc1dkR2lmNVV2TE5raGNIWjF5MnFVOW5GUkdZUWhERG5LZVJib0ZYLXlnMXhZM2pQLWIwV2…
Should I buy GT Biopharma (GTBP) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE9BR1V4X1k5MVhybmtlS2k2Rnh2Zy1ZR2xZb0NLREgyYTc4QmFzUGd5NDZsa0JET0psd0NGVG01dENROExSbkdSZEptUjJVVVg0U3NieGVFWUFZMXdkWHJDRzF6Nmlvb1NsTTVKTw?oc=5" target="_blank">Should I buy GT Bioph…
GTBP | GT Biopharma Inc. Common Insider Trading - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBlZE9vQ1ItSktqV2pOdHVkcEVzX2diUnFQMGxZc0NwZEpTa0FoeEJKSHE0UUFjTHZlQXo1RVU5MVNwcE4zcVpLenRvTDBSRFRvRE1JWUpVckNxcnM5?oc=5" target="_blank">GTBP | GT Biopharma Inc. Common Insider Tra…
GTBP — Frequently Asked Questions
What is the current share price of GTBP?
As of 2026-08-05 17:25 PDT, GTBP trades at $0.32 on NASDAQ/NYSE. Its 52-week range is $0.27 to $1.83.
What is the P/E ratio of GTBP?
GTBP trades at a trailing price-to-earnings (P/E) ratio of -0.05.
Is GTBP a good stock to buy?
This page provides a data-driven analysis of GTBP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.